Table 2 Patient characteristics at assay

Duration from onset of EGPA (months)

61.3 ± 100.7

75.1 ± 96.4

NS^*

BVAS at relapse or remission

14.5 ± 9.5

0 ± 0

< 0.01^*

Prednisolone dose at relapse or remission

10.4 ± 4.6

9.6 ± 7.6

NS^*

Immunosuppressant use at relapse or remission (%)

75

35.7

<0.05

CYC/AZA/CSA/MTX/RTX

7/1/1/0/0

3/2/0/0/0

NS^‡

No. of eosinophils in peripheral blood

350.8 ± 262.0

309.3 ± 273.2

NS^*

FOXP3⁺ cells among CD4⁺ T cells (%)

0.5 ± 0.4

5.8 ± 2.1

< 0.01^†

IL-10⁺ cells among CD4⁺CD25⁺ T cells (%)

0.3 ± 0.8

10.9 ± 11.4

< 0.01^†

TGF-β⁺ among CD4⁺CD25⁺ T cells (%)

0.2 ± 0.7

7.4 ± 6.1

< 0.01^†

IL-2⁺ among CD4⁺CD25⁻ T cells (%)

9.9 ± 14.1

32.2 ± 25.3

< 0.05^†